UNITED THERAPEUTICS Corp (UTHR) stock
UTHRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 11/3022% above fair value
$577.34−6.76 (-1.16%)
Close on Nov 18, 2026Market cap $24.76BP/E 20.7Yield –
United Therapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
United Therapeutics's revenue for the twelve months ending Jun 30, 2026 was $3.15B, up 2.5% year over year. For fiscal 2025 it was $3.18B, up 10.6% from the year before. Over ten years it grew 8.1% a year on average. The highest annual figure on record is $3.18B in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.18B | +10.6% |
| FY2024 | Dec 31, 2024 | $2.88B | +23.6% |
| FY2023 | Dec 31, 2023 | $2.33B | +20.2% |
| FY2022 | Dec 31, 2022 | $1.94B | +14.9% |
| FY2021 | Dec 31, 2021 | $1.69B | +13.6% |
| FY2020 | Dec 31, 2020 | $1.48B | +2.4% |
| FY2019 | Dec 31, 2019 | $1.45B | -11.0% |
| FY2018 | Dec 31, 2018 | $1.63B | -5.7% |
| FY2017 | Dec 31, 2017 | $1.73B | +7.9% |
| FY2016 | Dec 31, 2016 | $1.60B | +9.1% |
| FY2015 | Dec 31, 2015 | $1.47B | +13.8% |
| FY2014 | Dec 31, 2014 | $1.29B | +15.4% |
| FY2013 | Dec 31, 2013 | $1.12B | +21.9% |
| FY2012 | Dec 31, 2012 | $916.08M | +23.3% |
| FY2011 | Dec 31, 2011 | $743.18M | +25.3% |
| FY2010 | Dec 31, 2010 | $592.90M | +65.2% |
| FY2009 | Dec 31, 2009 | $358.88M | +27.5% |
| FY2008 | Dec 31, 2008 | $281.50M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $783.30M | -1.9% |
| Q1 FY2026 | Mar 31, 2026 | $781.50M | -1.6% |
| Q4 FY2025 | Dec 31, 2025 | $790.20M | +7.4% |
| Q3 FY2025 | Sep 30, 2025 | $799.50M | +6.8% |
| Q2 FY2025 | Jun 30, 2025 | $798.60M | +11.7% |
| Q1 FY2025 | Mar 31, 2025 | $794.40M | +17.2% |
| Q4 FY2024 | Dec 31, 2024 | $735.90M | +19.7% |
| Q3 FY2024 | Sep 30, 2024 | $748.90M | +22.9% |
| Q2 FY2024 | Jun 30, 2024 | $714.90M | +19.8% |
| Q1 FY2024 | Mar 31, 2024 | $677.70M | +33.7% |
| Q4 FY2023 | Dec 31, 2023 | $614.70M | +25.1% |
| Q3 FY2023 | Sep 30, 2023 | $609.40M | +18.1% |
| Q2 FY2023 | Jun 30, 2023 | $596.50M | +27.8% |
| Q1 FY2023 | Mar 31, 2023 | $506.90M | +9.7% |
| Q4 FY2022 | Dec 31, 2022 | $491.50M | +18.4% |
| Q3 FY2022 | Sep 30, 2022 | $516.00M | +16.0% |
| Q2 FY2022 | Jun 30, 2022 | $466.90M | +4.6% |
| Q1 FY2022 | Mar 31, 2022 | $461.90M | +21.8% |
| Q4 FY2021 | Dec 31, 2021 | $415.20M | +7.9% |
| Q3 FY2021 | Sep 30, 2021 | $444.70M | +17.0% |
| Q2 FY2021 | Jun 30, 2021 | $446.50M | +23.3% |
| Q1 FY2021 | Mar 31, 2021 | $379.10M | +6.4% |
| Q4 FY2020 | Dec 31, 2020 | $384.90M | +23.7% |
| Q3 FY2020 | Sep 30, 2020 | $380.10M | -5.3% |
| Q2 FY2020 | Jun 30, 2020 | $362.00M | -3.1% |
| Q1 FY2020 | Mar 31, 2020 | $356.30M | -1.7% |
| Q4 FY2019 | Dec 31, 2019 | $311.10M | -18.4% |
| Q3 FY2019 | Sep 30, 2019 | $401.50M | -2.7% |
| Q2 FY2019 | Jun 30, 2019 | $373.60M | -16.0% |
| Q1 FY2019 | Mar 31, 2019 | $362.60M | -6.8% |
| Q4 FY2018 | Dec 31, 2018 | $381.40M | -17.9% |
| Q3 FY2018 | Sep 30, 2018 | $412.70M | -7.4% |
| Q2 FY2018 | Jun 30, 2018 | $444.50M | -0.0% |
| Q1 FY2018 | Mar 31, 2018 | $389.20M | +5.0% |
| Q4 FY2017 | Dec 31, 2017 | $464.70M | +13.6% |
| Q3 FY2017 | Sep 30, 2017 | $445.50M | +9.1% |
| Q2 FY2017 | Jun 30, 2017 | $444.60M | – |
| Q1 FY2017 | Mar 31, 2017 | $370.50M | – |
| Q4 FY2016 | Dec 31, 2016 | $409.00M | – |
| Q3 FY2016 | Sep 30, 2016 | $408.20M | – |
See a number that looks wrong?